David G Brachman
Overview
Explore the profile of David G Brachman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
2553
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia M, Turner A, Brachman D
J Neurooncol
. 2024 Jan;
166(2):203-212.
PMID: 38261141
Malignant and benign brain tumors with a propensity to recur continue to be a clinical challenge despite decades-long efforts to develop systemic and more advanced local therapies. GammaTile (GT Medical...
2.
Pinnaduwage D, Srivastava S, Yan X, Jani S, Brachman D, Sorensen S
Technol Cancer Res Treat
. 2022 Jun;
21:15330338221106852.
PMID: 35712977
Brachytherapy using permanently implantable collagen tiles containing cesium-131 (Cs-131) is indicated for treatment of malignant intracranial neoplasms. We quantified Cs-131 source migration and modeled the resulting dosimetric impact for Cs-131,...
3.
Wefel J, Armstrong T, Pugh S, Gilbert M, Wendland M, Brachman D, et al.
Neuro Oncol
. 2021 Jan;
23(7):1125-1138.
PMID: 33515019
Background: Results of NRG Oncology RTOG 0825 reported adding bevacizumab to standard chemoradiation did not significantly improve survival endpoints and resulted in greater decline in neurocognitive function (NCF) and patient-reported...
4.
Bell E, Zhang P, Shaw E, Buckner J, Barger G, Bullard D, et al.
J Clin Oncol
. 2020 Jul;
38(29):3407-3417.
PMID: 32706640
Purpose: NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit...
5.
Brachman D, Youssef E, Dardis C, Sanai N, Zabramski J, Smith K, et al.
J Neurosurg
. 2018 Dec;
131(6):1819-1828.
PMID: 30579269
Objective: Effective treatments for recurrent, previously irradiated intracranial meningiomas are limited, and resection alone is not usually curative. Thus, the authors studied the combination of maximum safe resection and adjuvant...
6.
Meier R, Bloch D, Cotrutz C, Beckman A, Henning G, Woodhouse S, et al.
Int J Radiat Oncol Biol Phys
. 2018 Sep;
102(2):296-303.
PMID: 30191864
Purpose: The radiobiology of prostate cancer may favor the extreme hypofractionation inherent in stereotactic body radiation therapy (SBRT); however, data from a large multicenter study are lacking. We therefore examined...
7.
Hall W, Pugh S, Wefel J, Armstrong T, Gilbert M, Brachman D, et al.
Neurosurgery
. 2018 Apr;
84(1):66-76.
PMID: 29618054
Background: The influence of subtotal resection (STR) on neurocognitive function (NCF), quality of life, and symptom burden in glioblastoma is unknown. If bevacizumab preferentially benefits patients with STR is unknown....
8.
Blumenthal D, Won M, Mehta M, Gilbert M, Brown P, Bokstein F, et al.
Neuro Oncol
. 2018 Feb;
20(7):966-974.
PMID: 29462493
Background: We previously reported the unexpected finding of significantly improved survival for newly diagnosed glioblastoma in patients when radiation therapy (RT) was initiated later (>4 wk post-op) compared with earlier...
9.
van den Bent M, Baumert B, Erridge S, Vogelbaum M, Nowak A, Sanson M, et al.
Lancet
. 2017 Aug;
390(10103):1645-1653.
PMID: 28801186
Background: The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear....
10.
Brachman D
Int J Radiat Oncol Biol Phys
. 2015 Dec;
94(1):211.
PMID: 26700718
No abstract available.